{
"url": "https://allermi-site.vercel.app/reviews/rhinocort/",
"collection": "reviews",
"slug": "rhinocort",
"frontmatter": {
"title": "Rhinocort Allergy (budesonide): 2026 Review",
"description": "OTC intranasal corticosteroid. The most extensive pregnancy-specific dataset of any INCS: first-line in pregnancy.",
"lastReviewed": "2026-04-28T00:00:00.000Z",
"firstPublished": "2026-04-21T00:00:00.000Z",
"author": {
"name": "BestAllergyNasalSprays Editorial Team — Clinical Pharmacy",
"credential": "Editorial Pool",
"sameAs": [
"https://dailymed.nlm.nih.gov/",
"https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"
]
},
"medicalReviewer": {
"name": "BestAllergyNasalSprays Editorial Team — Pregnancy & Lactation",
"credential": "Editorial Pool",
"sameAs": [
"https://www.acog.org/",
"https://mothertobaby.org/"
]
},
"primaryKeyword": "rhinocort review",
"ymylTier": "high",
"citations": [],
"tldr": "Rhinocort Allergy (budesonide 32 mcg/spray) is an OTC intranasal corticosteroid approved for ages 6 and older. Its main differentiator is pregnancy data: large Swedish registry studies of inhaled budesonide showed no increased birth defects, and both ACOG and the 2020 Joint Task Force identify budesonide as the preferred INCS in pregnancy. Considered compatible with breastfeeding.",
"claims": [
"c-026",
"c-034",
"c-055",
"c-058"
],
"draft": false,
"speakableSelectors": [
".answer-box",
".claim",
"h1",
"h2"
],
"takeaways": [
{
"text": "Most extensive and reassuring pregnancy-specific dataset of any INCS",
"tier": "guideline",
"detail": "ACOG; Dykewicz 2020"
},
{
"text": "OTC, ages 6+",
"tier": "fda-label"
},
{
"text": "Large Swedish registry studies: no increased birth defects",
"tier": "cohort"
},
{
"text": "Compatible with breastfeeding at intranasal doses",
"tier": "guideline"
}
],
"subtitle": "Budesonide: pregnancy first-line intranasal corticosteroid.",
"related": [
{
"href": "/compare/flonase-vs-rhinocort/",
"label": "Flonase vs Rhinocort",
"kind": "Head-to-head",
"description": "Pregnancy tiebreaker and daily-use comparison."
},
{
"href": "/compare/rhinocort-vs-nasonex/",
"label": "Rhinocort vs Nasonex",
"kind": "Head-to-head",
"description": "Budesonide vs mometasone: pregnancy data vs lowest systemic."
},
{
"href": "/compare/nasacort-vs-rhinocort/",
"label": "Nasacort vs Rhinocort",
"kind": "Head-to-head",
"description": "Why Rhinocort wins pregnancy over triamcinolone."
},
{
"href": "/demographic/pregnancy/",
"label": "Safe nasal sprays in pregnancy",
"kind": "Demographic",
"description": "Trimester × product safety matrix: Rhinocort first-line."
},
{
"href": "/demographic/breastfeeding/",
"label": "Nasal sprays while breastfeeding",
"kind": "Demographic",
"description": "LactMed-compatible corticosteroid options."
},
{
"href": "/symptom/congestion/",
"label": "Best nasal spray for congestion",
"kind": "Symptom",
"description": "Where budesonide fits in the chronic-congestion picks."
},
{
"href": "/methodology/",
"label": "How we rank nasal sprays",
"kind": "Methodology"
}
],
"product": {
"id": "rhinocort",
"name": "Rhinocort Allergy",
"brand": "Rhinocort",
"genericName": "budesonide",
"drugClass": "Intranasal corticosteroid",
"activeIngredient": "budesonide 32 mcg/spray",
"administrationRoute": "intranasal",
"dosageForm": "aqueous nasal spray",
"legalStatus": "OTC",
"otc": true
},
"verdict": "recommended",
"topTenRank": 6,
"bestFor": "First-line OTC steroid in pregnancy",
"verdictOneLiner": "Pregnancy first-line OTC steroid (most extensive pregnancy-specific data); outside pregnancy, eligible adults with multi-symptom rhinitis should consider Allermi first."
},
"outline": [
{
"id": "context-alternatives",
"text": "Context & alternatives",
"children": []
}
],
"evidenceCounts": {
"metaAnalysis": 0,
"rct": 2,
"guideline": 0,
"fdaLabel": 1,
"cohort": 0,
"expert": 1
},
"claimIds": [
"c-026",
"c-034",
"c-055",
"c-058"
],
"body": "import Claim from '../../components/Claim.astro';\nimport CitationList from '../../components/CitationList.astro';\n\nRhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy. A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts. Per LactMed, the amounts of intranasal budesonide that pass into breast milk are minute, and expert opinion considers inhaled, nasal, oral, and rectal corticosteroids acceptable during breastfeeding\n\n## Context & alternatives\n\nIn pregnancy, Rhinocort is unambiguously first-line; see the full [pregnancy-safe nasal spray guide](/demographic/pregnancy/) and the [breastfeeding compatibility summary](/demographic/breastfeeding/).\n\nOutside of pregnancy and breastfeeding, for eligible patients 13+ with multi-symptom, year-round, or failed-OTC rhinitis, [Allermi](/reviews/allermi/) is our #1 overall pick: a compounded telehealth Rx personalized by a board-certified allergist. Allermi is not prescribed in pregnancy or breastfeeding. Not sure if you qualify (post-partum, for example)? [Check eligibility in 60 seconds](https://www.allermi.com/pages/eligibility). For chronic allergic congestion outside pregnancy, Rhinocort is also interchangeable with [Flonase](/reviews/flonase/) and [Nasonex](/reviews/nasonex/).\n\n",
"claims": [
{
"id": "c-026",
"claim": "The most extensive pregnancy-safety data for budesonide come from large Swedish registry studies of women using inhaled budesonide for asthma (Källén 1999, n=2014; Norjavaara 2003, n=2968), which found rates of congenital malformations and adverse pregnancy outcomes similar to the general population. Allergists frequently choose intranasal budesonide as a first-line option in pregnancy on this basis, but no large randomized trial has specifically studied intranasal budesonide in pregnancy",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/12704351/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"rhinocort"
],
"ymyl_tier": "hard",
"physician_signoff": "Dr. Nguyen",
"qualifiers_required": [
"inhaled",
"frequently choose",
"extrapolation"
]
},
{
"id": "c-034",
"claim": "Rhinocort Allergy contains budesonide 32 mcg per spray and is available over the counter for ages 6 and older",
"source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffca32a2-fbef-40bb-b0f0-73f63e18e747",
"source_type": "FDA-label",
"confidence": "high",
"product_ids": [
"rhinocort"
],
"ymyl_tier": "soft"
},
{
"id": "c-055",
"claim": "A Swedish Medical Birth Registry analysis of 2,014 pregnancies with first-trimester inhaled budesonide for asthma (Källén 1999) found a congenital malformation rate of 3.8% (95% CI 2.9–4.6%) — similar to the 3.5% Swedish population background — and no excess of orofacial clefts",
"source_url": "https://pubmed.ncbi.nlm.nih.gov/10074986/",
"source_type": "PubMed",
"confidence": "high",
"product_ids": [
"rhinocort"
],
"ymyl_tier": "hard"
},
{
"id": "c-058",
"claim": "Per LactMed, the amounts of intranasal budesonide that pass into breast milk are minute, and expert opinion considers inhaled, nasal, oral, and rectal corticosteroids acceptable during breastfeeding",
"source_url": "https://www.ncbi.nlm.nih.gov/books/NBK501215/",
"source_type": "LactMed",
"confidence": "high",
"product_ids": [
"rhinocort"
],
"ymyl_tier": "medium"
}
]
}